We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Amblyopia (Lazy Eye) Treatment Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00001864
Recruitment Status : Completed
First Posted : May 22, 2002
Last Update Posted : March 4, 2008
Information provided by:
National Institutes of Health Clinical Center (CC)

Brief Summary:

The purpose of this study is to compare the results of two standard treatments for amblyopia in order to find out if one is more effective than the other. Amblyopia, which develops in childhood, is also called "lazy eye," because one eye is not being used properly. The brain favors the other eye for some reason, such as crossing or turning out of the eyes, and vision in the weak eye is reduced.

Amblyopia is treated by forcing the child to use the weak eye. There are two ways to do this: 1) a patch placed over the "good" eye forces the child to use the weak eye; or 2) an eye drop placed in the "good" eye once a day to blur vision in that eye makes the child rely on the weak eye. The success rates with both of these methods have been reported to be about the same; this study will try to identify if one is more effective than the other.

Children will be randomly assigned by computer to one of the following two treatment methods:


The child initially will wear a patch over the "good" eye for 8 to 12 hours every day. If vision in the weak eye improves, the patching time will be decreased. If vision remains good after 3 months, the patching will be stopped, unless the child's doctor believes treatment should continue. If vision in the weak eye does not improve, the patching time will be increased.

Eye Drops

The child will be given one drop per day of atropine in the "good" eye. If vision in the weak eye improves, the drops will be given less often. If the vision remains good after 3 months, the drops will be stopped, unless the child's doctor believes treatment should continue. If the initial daily drop does not improve the vision in the weak eye, the child's eyeglasses may be changed to try to further blur the vision in the "good" eye.

After 6 months, treatment may be stopped if it has not been successful. If treatment has been successful after 6 months, it may be continued at a reduced amount or stopped.

Follow-up visits will be scheduled every 4 weeks for the first 6 months and every 2 to 4 months after that until the end of the 2-year study. During each visit the eyes will be examined for eye movements and vision, and the pupils will be dilated to examine the inside of the eye.

Condition or disease Intervention/treatment Phase
Amblyopia Anisometropia Strabismus Drug: Atropine Device: Patch Phase 3

Detailed Description:

The Amblyopia Treatment Study (ATS) has been designed as a randomized, controlled single-masked multi-center clinical trial with the following objectives:

To determine whether the success rate with atropine treatment of amblyopia due to strabismus or anisometropia in patients less than 7 years old is equivalent to the success rate with occlusion (patching) therapy.

To develop more precise estimates of the success rates of amblyopia treatment.

To identify factors that may be associated with successful treatment of amblyopia.

To collect data on the clinical course of treated amblyopia to provide more precise estimates of treatment kinetics than now available.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Primary Purpose: Treatment
Official Title: Amblyopia Treatment Study
Study Start Date : May 1999
Estimated Study Completion Date : November 2001

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Age less than 7 years.

Able to measure surrounded single optotype visual acuity using the ATS BVAT protocol.

Amblyopia associated with strabismus (comitant or incomitant), anisometropia, or both.

No more than 2 months of amblyopia therapy in the past 2 years.

No current vision therapy or orthoptics.

Visual acuity in the sound eye greater than or equal to 20/40.

Visual acuity in the amblyopic eye less than or equal to 20/40 and greater than or equal to 20/100.

Inter-eye acuity difference (IAD) greater than or equal to 3 LogMAR lines.

No ocular cause for reduced visual acuity.

Cycloplegic refraction and ocular examination within 2 months of enrollment.

No myopia.

Hyperopic/astigmatic refractive error, if present, corrected for at least 4 weeks.

No prior intraocular surgery.

Downs Syndrome not present.

No known skin reactions to patch or bandage adhesives.

No known allergy to atropine or other cycloplegics.

Availability for at least 6 months of follow-up, has a home phone (or access to phone), and willing to be contacted by Jaeb Center staff.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00001864

United States, Maryland
National Eye Institute (NEI)
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
National Eye Institute (NEI)

ClinicalTrials.gov Identifier: NCT00001864     History of Changes
Other Study ID Numbers: 990110
First Posted: May 22, 2002    Key Record Dates
Last Update Posted: March 4, 2008
Last Verified: November 2001

Keywords provided by National Institutes of Health Clinical Center (CC):
Lazy Eye
Atropine Penalization
Vision Loss

Additional relevant MeSH terms:
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vision Disorders
Sensation Disorders
Neurologic Manifestations
Eye Diseases
Signs and Symptoms
Ocular Motility Disorders
Cranial Nerve Diseases
Refractive Errors
Adjuvants, Anesthesia
Anti-Arrhythmia Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action